Critical Comparison: Integrated BioPharma (OTCMKTS:INBP) versus ARS Pharmaceuticals (NASDAQ:SPRY)

Integrated BioPharma (OTCMKTS:INBP) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Insider & Institutional Ownership

25.3% of Integrated BioPharma shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 67.4% of Integrated BioPharma shares are owned by insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Integrated BioPharma and ARS Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integrated BioPharma	1.26%	3.32%	2.64%
ARS Pharmaceuticals	-56.06%	-38.77%	-23.46%

Analyst Recommendations

This is a summary of current recommendations for Integrated BioPharma and ARS Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated BioPharma	0	0	0	0	0.00
ARS Pharmaceuticals	1	1	4	0	2.50

ARS Pharmaceuticals has a consensus price target of $33.00, suggesting a potential upside of 210.44%. Given ARS Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Integrated BioPharma.

Earnings & Valuation

This table compares Integrated BioPharma and ARS Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated BioPharma	$54.35 million	0.21	$810,000.00	$0.01	36.85
ARS Pharmaceuticals	$89.15 million	11.79	$8.00 million	($0.81)	-13.12

ARS Pharmaceuticals has higher revenue and earnings than Integrated BioPharma. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Integrated BioPharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Integrated BioPharma has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Summary

ARS Pharmaceuticals beats Integrated BioPharma on 8 of the 14 factors compared between the two stocks.

About Integrated BioPharma

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.